Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer.

ABSTRACT: The pathologic definition of triple negative breast cancer (TNBC) relies on the absence of expression of estrogen, progesterone and HER2 receptors. However, this BC subgroup is distinguished by a wide biological, molecular and clinical heterogeneity. Among the intrinsic TNBC subtypes, the mesenchymal type is defined by the expression of genes involved in the epithelial to mesenchymal transition, stromal interaction and cell motility. Moreover, it shows a high expression of genes involved in proliferation and an immune-suppressive microenvironment. Several molecular alterations along different pathways activated during carcinogenesis and tumor progression have been outlined and could be involved in immune evasion mechanisms. Furthermore, reverting epithelial to mesenchymal transition proces

SUBMITTER: Mezi S 

PROVIDER: S-EPMC7959307 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature